NCT02303769View on ClinicalTrials.gov

Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS

PHASE3CompletedINTERVENTIONAL
Enrollment

309

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

October 31, 2015

Conditions
Benign Prostatic Hyperplasia
Interventions
DRUG

Tamsulosin HCL 0.4mg

Tamsulosin HCL 0.4mg once a day

DRUG

Tamsulosin HCL 0.2mg

Tamsulosin HCL 0.2mg once a day

Trial Locations (1)

Unknown

Eulji general hospital, Seoul

Sponsors
All Listed Sponsors
lead

GL Pharm Tech Corporation

INDUSTRY